TABLE 1.
Patient demographics and genetic information.
| Parameter | All patients | Patients with LGG | Patients with GBM |
| WHO tumor grade | 91 | 48 (52.7%) | 43 (47.2%) |
| Mean age (y)* | 47.1 ± 12.6 | 44.3 ± 11.7 | 50.3 ± 12.9 |
| No. of women | 45 (49.4%) | 28 (58.3%) | 17 (39.5%) |
| IDH gene status | |||
| Mutated | 38 (41.7%) | 31 (64.5%) | 7 (16.2%) |
| Wild type | 48 (52.7%) | 15 (31.2%) | 33 (76.7%) |
| NA | 5 (5.4%) | 2 (4.1%) | 3 (6.9%) |
| MGMT promoter methylation | |||
| Methylated | 34 (37.3%) | 22 (45.8%) | 12 (27.9%) |
| Unmethylated | 55 (60.4%) | 26 (54.1%) | 29 (67.4%) |
| NA | 2 (2.1%) | 0 (0) | 2 (4.6%) |
| RTKs alterations (amplification, mutation) | |||
| No. of patients | 53 (58.2%) | 26 (49.0%) | 27 (50.9%) |
| EGFR | 28 (52.8%) | 7 (26.9%) | 21 (77.8%) |
| PDGFRA | 8 (15.1%) | 2 (7.7%) | 6 (22.2%) |
| MET | 9 (17.0%) | 4 (15.4%) | 5 (18.5%) |
| VEGFR2 | 7 (13.2%) | 3 (11.5%) | 4 (14.8%) |
Unless otherwise indicated, data are number of patients, with percentages in parentheses. ∗Data are means ± standard deviations.
NA, not applicable; LGG, lower-grade glioma; WHO, World Health Organization; IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine-DNA-methyltransferase; RTKs, receptor tyrosine kinases; CNV, copy number variation.